The association of FKBP51 with stress-related disorders and neurodegenerative diseases, together with the protective effects seen with FKBP51 depletion in animal models of depression and anxiety make this co-chaperone a promising drug target. The gene discussed is FKBP4; the disease is depressive symptom measurement.